Glucagon Like Peptide-1 (GLP-1) Agonists Market Report

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 07, 2022
  • PAGES：223
  • REPORT CODE：GMM833921
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

    AstraZeneca, GSK, Bristol-Myers Squibb, Novo Nordisk, Eli Lilly are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.

    Glucagon Like Peptide-1 (GLP-1) Agonists market report explains the definition, types, applications, major countries, and major players of the Glucagon Like Peptide-1 (GLP-1) Agonists market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • AstraZeneca

    • GSK

    • Bristol-Myers Squibb

    • Novo Nordisk

    • Eli Lilly

    • Sanofi

    • Amylin

    By Type:

    • Exenatied

    • Liraglutide

    • Lixisenatide

    • Albiglutide

    • Dulaglutide

    By End-User:

    • Hospital

    • Pharmacy

    • Other

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Glucagon Like Peptide-1 (GLP-1) Agonists Outlook to 2028- Original Forecasts

    • 2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market- Recent Developments

    • 6.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market News and Developments

    • 6.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Deals Landscape

    7 Glucagon Like Peptide-1 (GLP-1) Agonists Raw Materials and Cost Structure Analysis

    • 7.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials

    • 7.2 Glucagon Like Peptide-1 (GLP-1) Agonists Price Trend of Key Raw Materials

    • 7.3 Glucagon Like Peptide-1 (GLP-1) Agonists Key Suppliers of Raw Materials

    • 7.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Rate of Raw Materials

    • 7.5 Glucagon Like Peptide-1 (GLP-1) Agonists Cost Structure Analysis

      • 7.5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Raw Materials Analysis

      • 7.5.2 Glucagon Like Peptide-1 (GLP-1) Agonists Labor Cost Analysis

      • 7.5.3 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Expenses Analysis

    8 Global Glucagon Like Peptide-1 (GLP-1) Agonists Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Export by Region (Top 10 Countries) (2017-2028)

    9 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Outlook by Types and Applications to 2022

    • 9.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Exenatied Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Liraglutide Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Lixisenatide Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Albiglutide Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Dulaglutide Consumption and Growth Rate (2017-2022)

    • 9.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Pharmacy Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Outlook till 2022

    • 10.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.2.2 Canada Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.2.3 Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.3.2 UK Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.3.3 Spain Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.3.4 Belgium Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.3.5 France Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.3.6 Italy Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.3.7 Denmark Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.3.8 Finland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.3.9 Norway Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.3.10 Sweden Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.3.11 Poland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.3.12 Russia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.3.13 Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.4.2 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.4.3 India Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.4.4 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.4.5 Pakistan Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.4.6 Bangladesh Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.4.7 Indonesia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.4.8 Thailand Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.4.9 Singapore Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.4.10 Malaysia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.4.11 Philippines Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.4.12 Vietnam Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.5.2 Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.5.3 Chile Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.5.4 Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.5.5 Venezuela Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.5.6 Peru Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.5.7 Puerto Rico Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.5.8 Ecuador Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.6.2 Kuwait Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.6.3 Oman Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.6.4 Qatar Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.7.2 South Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.7.3 Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.7.4 Algeria Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

      • 10.8.2 New Zealand Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    11 Global Glucagon Like Peptide-1 (GLP-1) Agonists Competitive Analysis

    • 11.1 AstraZeneca

      • 11.1.1 AstraZeneca Company Details

      • 11.1.2 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

      • 11.1.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 GSK

      • 11.2.1 GSK Company Details

      • 11.2.2 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

      • 11.2.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Bristol-Myers Squibb

      • 11.3.1 Bristol-Myers Squibb Company Details

      • 11.3.2 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

      • 11.3.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Novo Nordisk

      • 11.4.1 Novo Nordisk Company Details

      • 11.4.2 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

      • 11.4.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Eli Lilly

      • 11.5.1 Eli Lilly Company Details

      • 11.5.2 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

      • 11.5.4 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Sanofi

      • 11.6.1 Sanofi Company Details

      • 11.6.2 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

      • 11.6.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Amylin

      • 11.7.1 Amylin Company Details

      • 11.7.2 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

      • 11.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    12 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Outlook by Types and Applications to 2028

    • 12.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Exenatied Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Liraglutide Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Lixisenatide Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Albiglutide Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Dulaglutide Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Pharmacy Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Outlook to 2028

    • 13.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.2.2 Canada Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.3.2 UK Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.3.3 Spain Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.3.5 France Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.3.6 Italy Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.3.8 Finland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.3.9 Norway Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.3.11 Poland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.3.12 Russia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.4.2 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.4.3 India Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.5.3 Chile Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.5.6 Peru Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.6.3 Oman Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Glucagon Like Peptide-1 (GLP-1) Agonists

    • Figure of Glucagon Like Peptide-1 (GLP-1) Agonists Picture

    • Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Exenatied Consumption and Growth Rate (2017-2022)

    • Figure Global Liraglutide Consumption and Growth Rate (2017-2022)

    • Figure Global Lixisenatide Consumption and Growth Rate (2017-2022)

    • Figure Global Albiglutide Consumption and Growth Rate (2017-2022)

    • Figure Global Dulaglutide Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Pharmacy Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Country (2017-2022)

    • Table North America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Country (2017-2022)

    • Figure United States Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Canada Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Table Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Country (2017-2022)

    • Figure Germany Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure UK Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Spain Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Belgium Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure France Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Italy Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Denmark Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Finland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Norway Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Sweden Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Poland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Russia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Table APAC Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Country (2017-2022)

    • Figure China Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Japan Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure India Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Thailand Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Singapore Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Philippines Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Table South America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Country (2017-2022)

    • Figure Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Chile Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Peru Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Table GCC Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Country (2017-2022)

    • Figure Bahrain Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Oman Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Qatar Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Table Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Country (2017-2022)

    • Figure Nigeria Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure South Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Algeria Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Table Oceania Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Country (2017-2022)

    • Figure Australia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Table AstraZeneca Company Details

    • Table AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

    • Table AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

    • Table GSK Company Details

    • Table GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table GSK Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

    • Table GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

    • Table Bristol-Myers Squibb Company Details

    • Table Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

    • Table Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

    • Table Novo Nordisk Company Details

    • Table Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

    • Table Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

    • Table Eli Lilly Company Details

    • Table Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

    • Table Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

    • Table Sanofi Company Details

    • Table Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

    • Table Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

    • Table Amylin Company Details

    • Table Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Main Business and Markets Served

    • Table Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio

    • Figure Global Exenatied Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Liraglutide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Lixisenatide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Albiglutide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Dulaglutide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pharmacy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast by Country (2022-2028)

    • Table North America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast by Country (2022-2028)

    • Figure United States Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast by Country (2022-2028)

    • Figure Germany Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast by Country (2022-2028)

    • Figure China Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast by Country (2022-2028)

    • Figure Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast by Country (2022-2028)

    • Figure Australia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US